# Abstract

To report findings through 24 months of a 36 month trial of signs of corneal health, subjective symptoms and safety with continuous wear of NIGHT&DAY (N&D) lenses and low Dk daily wear (DW) 2-week replacement soft contact lenses. 317 patients were dispensed to wear N&D for up to 30N CW and 81 neophyte patients were dispensed in a lens for DW. Clinical and subjective data were collected at follow-up visits for each group.

A cohort of 240 N&D and 58 DW patients completed all visits through 24 months. 30N CW was recommended for all N&D patients by the 24 month visit. For the N&D cohort, improvements in biomicroscopy grades were most dramatic within 1 week for limbal (p<0.001) and conjunctival (p<0.001) redness with 5 of 10 signs improving and 5 unchanged through 24 months. For the DW cohort, 4 of 10 signs worsened and 6 were unchanged through 24 months. For subjective symptoms, end of day dryness improved in both frequency (p<0.001) and severity (p<0.001) among 11% of patients in N&D, while 11% more patients in the DW group reported more frequent (p=0.014) and severe (p=0.014) end of day dryness. The percentage of eyes achieving 20/20 VA in the N&D cohort improved from 78% at dispensing to 86% at 12 months (p=0.995) and 86% at 24 months (p=0.011). For DW, 87%, 64% and 66% of eyes had 20/20 VA or better at dispensing, 12 (p=0.001), and 24 (p=0.001) months, respectively. Discontinuations totaled 24% for N&D and 27% for DW, with 1 discontinuation in each group from a potential adverse event. Microbial keratitis did not occur in either group.

N&D worn for 30N CW performed very well for biomicroscopy signs while DW results were mixed. In the N&D group, 5 signs of corneal health improved and none declined. In the DW group no signs improved and 4 signs declined. VA improved in the N&D group and declined in the DW group. N&D also showed improvement in end of day dryness symptoms. In these cohorts through 24 months, N&D worn for 30N CW may be healthier than DW lenses based on signs of corneal health, improvement in end of day dryness, and VA. It is an interesting finding that the prevalence of signs and symptoms in the DW cohort were generally greater than that in the CW cohort. Further research is warranted to clarify the impact of these findings on overall corneal health.

Investigators	
Principal Investigator	Location
Joseph T. Barr, OD	Columbus, OH
Steve Bennett, OD	Ann Arbor, MI
Peter Bergenske, OD	Forest Grove, OR
Walter Choate, OD	Madison, TN
Bobby Christensen, OD	Midwest City, OK
DC Dean, OD	Albuquerque, NM
Peter Donshik, MD	Bloomfield, CT
Barry Eiden, OD	Deerfield, IL
Art Epstein, OD	Roslyn, NY
Michael Goldsmid, OD	San Diego, CA
Barry Kissack, OD	Honeoye Falls, NY
Lee Rigel, OD	East Lansing, MI
Ellen Rogers, OD	Jacksonville, FL
Joe Schwallie, OD	Holland, OH
Glenda Secor, OD	Huntington Beach, CA
Christine Sindt, OD	Iowa City, IA
Vivien Smith, OD	Lexington, KY
Joe Yager, OD	Orlando, FL

	FND group	DW group
Gender distribution (n, %)		
Female	211, 67%	54, 63%
Male	106, 33%	30, 35%
Not reported	0,0%	2, 2%
Age (years)		
Average + sd	37.6 + 11.1	22.7 + 11.7
Maximum	72	54
Minimum	13	9
Spectacle refraction (average + sd, max, min)		
Sphere power in diopters	-3.36 + 2.71, -10.75, +6.50	-1.79 + 1.74, -7.75, +2.75
Cylinder power in diopters	-0.31 + 0.34, -1.50, 0.00	-0.30 + 0.36, -2.25, 0.00
Axis in degrees	64° + 69°, 0°, 180°	59° + 61°, 0°, 180°
Keratometry (average + sd, max, min)		
Horizontal power in diopters	44.09 + 1.45, 39.50, 49.13	43.60 + 1.41, 39.25, 47.00
Vertical power in diopters	44.66 + 1.50, 39.75, 49.62	44.16 + 1.41, 40.75, 47.75
Axis in degrees	92° + 37°, 0°, 180°	91° + 35°, 3°, 180°
Contact lens experience (n, %)		
Current SCL wearer.	286, 90%	0
Former SCL wearer.	26, 8%	15, 17%
New SCL wearer.	5, 2%	71, 83%

# 24 Month Update of a Multicenter Trial of Silicone Hydrogel Soft Contact Lenses

SSD


NSD

0.149

0.819


Joseph T. Barr, MS, OD; Peter Bergenske, OD; Peter Donshik, MD; Glenda Secor, OD; John Yoakum, OD; Sally M. Dillehay, MS, OD, EdD; Bill Long, BS






Papillary conjunctivitis

Corneal ulcer



DW Frequency of Symptoms (None or Sometimes) Through 24 Months



Symptom	p 24 mo	statistical sig*	
Discomfort upon insertion			
Dryness during the day	0.317	NSD	
Dryness at end of day	0.014	NSD	
Redness	0.157	NSD	
Burning or stinging	1.000	NSD	
Blurred vision	0.999	NSD	
Mucous in the morning	0.157	NSD	
Tearing & watering	0.317	NSD	
Itching	0.157	NSD	
Sensitivity to bright lights	0.564	NSD	
Lens awareness	0.317	NSD	
Average			

\*p < 0.005, Bonferroni adjusted

Symptom	p 24 mo	statistical sig*	
Discomfort upon insertion			
Dryness at end of day	0.001	SSD	
Dryness during the day	0.004	SSD	
Redness	0.007	NSD	
Burning or stinging	0.225	NSD	
Blurred vision	0.371	NSD	
Mucous in the morning	0.071	NSD	
Tearing & watering	0.020	NSD	
Itching	0.166	NSD	
Sensitivity to bright lights	0.001	SSD	
Lens awareness	0.022	NSD	
Average			
*t < 0.005 Ronferroni adjusted			

~p < 0.005, Bonjerroni adjusted

\*p < 0.005, Bonferroni adjusted

Change in Average Biomicroscopy Signs Through 24 Months for N&D Cohort

unchanged improved improved improved

Bio Sign

Conjunctival staining

Limbal redness

Corneal staining

Corneal infiltrates

Corneal edema

Corneal ulcer

Epithelial microcysts

Conjunctival redness

Papillary conjunctivitis

\*p < 0.005, Bonferroni adjusted

N&D Frequency of Symptoms (None or Sometimes) Through 24 Months

N&D Severity of Symptoms (None or Mild) Through 24 Months

■ Baseline ■ 24 MO

■ Baseline ■ 24 MO

Symptom	p 24 mo	statistical sig*	
Discomfort upon insertion			
Dryness during the day	0.564	NSD	
Dryness at end of day	0.014	NSD	
Redness	0.083	NSD	
Burning or stinging	0.317	NSD	
Blurred vision	0.102	NSD	
Mucous in the morning	0.317	NSD	
Tearing & watering	0.317	NSD	
Itching	0.317	NSD	
Sensitivity to bright lights	0.317	NSD	
Lens awareness	1.000	NSD	
Average			

\*p < 0.005, Bonferroni adjusted

# % of Eyes with 20/20 or Better Visual Acuity 78%

Discontinuations in CW Lotrafilcon A Group Through 24 Months  N&D Arm						
	dispensing to 1-week	1-week to 1-month	1-month to 6-months	6-months to 12-months	12-months to 24-months	total
discomfort	3%	2%	1%	2%	0%	7%
disinterest	1%	1%	0%	1%	0%	3%
lost-to-follow up, relocated	1%	0%	3%	2%	1%	7%
unacceptable subjective vision	1%	0%	1%	0%	0%	2%
unacceptable fit	0%	0%	0%	0%	0%	0%
other	0%	0%	0%	1%	1%	3%
subjective symptoms	0%	0%	0%	1%	0%	1%
positive biomicroscopy	0%	0%	0%	0%	0%	0%
total	7%	3%	5%	6%	2%	24%

# DW Arm, adjusted for inclusion/exclusion dc's 0% 0% lost-to-follow up, relocated 0% 0% 16% 6% 4% 27%

Discontinuations in Low Dk Group Through 24 Months

## Summary

### Biomicroscopy

- Lotrafilcon A: Continued improvement through 24 months
- Low Dk DW: Most signs worsened or unchanged

### Visual acuity

- Lotrafilcon A: Improvements through 24 months
- Low Dk DW: Worsened through 24 months

- Lotrafilcon A: Improvements in frequency & severity. Fewer patients with c/o dryness
- Low Dk DW: Four of ten symptoms worsened

### Discontinuations

About equal between the groups

# Acknowledgements

Carla Mack, OD, FAAO Jeff Schaffer, OD, FAAO